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Abstract
Animals that accurately model human disease are invaluable in medical research, allowing a critical understanding
of disease mechanisms, and the opportunity to evaluate the effect of therapeutic compounds in pre-clinical studies.
Many types of animal models are used world-wide, with the most common being small laboratory animals, such as
mice. However, rodents often do not faithfully replicate human disease, despite their predominant use in research.
This discordancy is due in part to physiological differences, such as body size and longevity. In contrast, large
animal models, including sheep, provide an alternative to mice for biomedical research due to their greater
physiological parallels with humans. Completion of the full genome sequences of many species, and the advent of
Next Generation Sequencing (NGS) technologies, means it is now feasible to screen large populations of
domesticated animals for genetic variants that resemble human genetic diseases, and generate models that more
accurately model rare human pathologies. In this review, we discuss the notion of using sheep as large animal
models, and their advantages in modelling human genetic disease. We exemplify several existing naturally occurring
ovine variants in genes that are orthologous to human disease genes, such as the Cln6 sheep model for Batten disease.
These, and other sheep models, have contributed significantly to our understanding of the relevant human disease
process, in addition to providing opportunities to trial new therapies in animals with similar body and organ size to
humans. Therefore sheep are a significant species with respect to the modelling of rare genetic human disease, which
we summarize in this review.
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Introduction
Based on the number of genes involved, genetic dis-
eases can be categorised into simple monogenic dis-
eases, which tend to be rare, or polygenic diseases,
which are much more common and multifactorial in
nature. However, the principal difference between rare
monogenic and common diseases is their mode of in-
heritance; only monogenic diseases follow a typical
Mendelian pattern of inheritance [1]. The identifica-
tion of novel mutations causing genetic disease has
seen more progress in the last few years than in the
previous twenty. This increased body of research has
resulted in a wealth of information regarding rare dis-
eases and is publicly available through projects like
the HapMap project [2] (http://hapmap.ncbi.nlm.nih.-
gov/) and the Online Mendelian Inheritance in Man
[3] (http://www.ncbi.nlm.nih.gov/omim). Identifying
the underlying cause of disease is the first step in de-
veloping an effective treatment, and it can take sev-
eral years to decades for an effective treatment of any
given pathological disorder to be available. Until re-
cently, identifying the causative gene in a given dis-
order could be a very time consuming process. Now
with the advent of next generation sequencing (NGS)
techniques, many large-scale genomic projects for the
study of rare genetic diseases have come into effect.
For instance, “The Undiagnosed Diseases Program” at
National Institutes of Health (NIH), which started in
May, 2008 [4], employed exome sequencing to screen
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patients who presented with previously undiagnosed
genetic disorders and successfully diagnosed 39 pa-
tients in the first two years [4, 5].
Rare genetic diseases
Several challenges exist in the study of rare genetic dis-
ease. Most of the monogenic diseases of unknown gen-
etic cause are present at a very low rate in the human
population. Among the nearly seven thousand rare gen-
etic diseases that are known in humans, there are disor-
ders so rare that their condition is limited to just a small
number of reported cases in the world, for example
Ablepharon-Macrostomia syndrome [6]. Researchers
face significant difficulties in identifying patients with a
particular rare disease of interest and obtaining sufficient
numbers of patients for analysis. In addition, the total
amount of funding available for research focused on rare
genetic disease is scarce. Nevertheless, orphan diseases
cannot be ignored, as collectively they pose a heavy bur-
den on society. Seventy five percent of rare diseases
affect children, and 30 % of these children die within the
first five years of life. In addition, studying rare mono-
genic diseases significantly contributes to our under-
standing of both monogenic and polygenic diseases [7].
Following a conference involving 30 rare genetic
disease groups in New Zealand, the New Zealand
Organization for Rare Disorders (NZORD) was estab-
lished as a charitable trust in the year 2000, and now
has a network of 165 rare disease support and infor-
mation groups. Its main aims are to help people af-
fected by rare diseases, to create awareness about rare
diseases, promote improvements to health care and
social supports, and facilitate research into rare dis-
eases by networking with researchers, affected pa-
tients, clinicians and policy makers. Information
regarding various rare diseases is also made available
publicly through their website, which links to other
rare disease organizations across the world. NZORD
promotes rare disease research through their charit-
able company the New Zealand Institute for Rare
Disease Research Ltd (NZIRDR). NZIRDR has re-
cently started a human tissue biobank, is maintaining
a register of researchers in New Zealand with an
interest in rare disease research, and is actively inves-
tigating prevalence and costs of rare diseases in New
Zealand. It also has a database of animal models of
human diseases, which occur naturally in New Zeal-
and’s farm animal populations, and is planning a sig-
nificant step forward in their genomics research
initiatives through an active search for more large
animal models. A complete list of all the animal models
is available at the NZIRDR animal models web page [8]
(www.nzirdr.org.nz/animal_models/our_models).
Review: animal models and human disease
Many genes and their functions are highly conserved
throughout the animal kingdom, and at the cellular level
many biological processes are very similar between spe-
cies, including cell proliferation, metabolism, and growth
regulation. This homology across species is key to con-
sidering the possibility of studying diseases and their
underlying molecular mechanisms in animal models of
genetic disease. Indeed, animal models have been crucial
in understanding both genetic diseases [9] and non-
genetic diseases [10], alike. Furthermore, whole genome
sequencing initiatives have now provided access to gen-
ome sequence information for approximately 60 species,
including sheep and cattle, in addition to model organ-
isms such as mice and zebrafish.
Animal models of human genetic disorders can pro-
vide excellent opportunities for pre-clinical studies to
develop treatments for human disease. Choosing the ap-
propriate animal model to address a biomedical research
question is a complex process. Mice are very good
models for biomedical studies, not least because of their
short reproductive cycle, increasingly well-known genet-
ics, ability to genetically manipulate embryos to create
stable mouse lines, and small size [11]. Since the intro-
duction of gene knockout technologies more than
25 years ago, thousands of gene knockout mouse models
are now available. An ideal transgenic mouse model of
human disease has a robust phenotype, well-defined ab-
normalities and pathological features that replicate the
human disease well [11].
Examples of knockout mouse models of human dis-
ease include inherited neurodegenerative diseases, such
as for example Huntington’s disease [12], Parkinson’s
disease (PD) [13, 14], autosomal dominant polycystic
kidney disease [15], and skeletal diseases such as Stickler
syndrome [16]. While mouse models of human genetic
disease have contributed significantly to the understand-
ing of various genetic diseases, several factors limit mice
as models of human disease. For instance, there are no
reported cases of naturally occurring PD in any animal
species to the best of our knowledge. Most PD mouse
models are toxin induced, where chemicals like1-
methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP),
paraquat or rotenone are used to produce nigrostriatial
dopaminergic lesions. Although most of the toxin-
induced mouse models affect mitochondrial function
and/or create free oxygen radicals, none of them com-
pletely reproduce the pathology and clinical symptoms
of the PD seen in humans [13]. In spite of their extensive
use to study the disease, the results obtained using these
models have not so far been successfully translated to
the clinic. Furthermore, neurodegenerative diseases like
PD and Alzheimer’s disease occur in an elderly popula-
tion, usually over 60 years of age, making the short life
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span of rodents a limiting factor. The complexity and
genetic heterogeneity of diseases such as PD have a huge
impact on whether mouse genetic models successfully
model the human disease. Mutations in the gene Lrrk2
account for 5–6 % of patients with familial PD and 1–
3 % of sporadic cases, but most Lrrk2 transgenic mouse
models showed minimal or no neurodegeneration [14].
There are many factors that impact on the therapeutic
leap from genetic models to humans and this has been ex-
tensively reviewed for Huntington’s disease [17]. The
shortcomings of mouse models for Huntington’s disease
can be extrapolated to other genetic diseases with a late
onset. Recently, a study investigated the genetic similar-
ities of humans with inflammatory disease with different
etiologies and concluded that although the conditions in
humans share a high similarity, the corresponding murine
models correlate poorly to the human conditions [18].
This study further indicated that there is a need for read-
dressing the current animal models and raised concerns
over the feasibility of translational medical research using
simple mouse models [18]. A possible solution for this is
therefore to employ multiple animal models.
Naturally occurring variants of human genetic diseases in
animal counterparts
One of the most exciting land-marks in large animal re-
search was marked by the successful cloning of the sheep
named Dolly in 1996 [19]. This was a major leap forward in
transgenic research and has led to the successful cloning of
thousands of animals from 20 different species. There are
many viable applications for this technology ranging from
creating high-value farm animals, to producing transgenic
animals or creating animal models for research.
Scientific awareness of the benefit of using large ani-
mal models in genetic research is increasing, as large
animal models are more similar to humans in relation to
size, lifespan, and certain clinical signs and physiology,
than rodent models. They also have had a long history
of use in medical research. Over the past few decades,
large animal models, including sheep, have played im-
portant roles in preclinical trials [20], resulting in signifi-
cant progress in the understanding of the pathological
mechanisms of both complex and Mendelian genetic
diseases. With the current lack of success in clinical tri-
als, with less that 20 % proceeding past Phase II [21] the
relevance of large animal models for pre-clinical work
may become more apparent.
Progress in understanding genotype-phenotype rela-
tionships in human patients, has been facilitated by the
study of animals with mutations in orthologous genes.
Such animal orthologs are an important aid to the devel-
opment of specific gene therapies for these disorders.
There exist many animal models where naturally occur-
ring disease-causing mutations that are homologous to
mutations in the equivalent human disease have been
discovered. Animal models that closely match the dis-
ease causing mutation in humans, like the Cln6 ovine
model of Batten disease (BD) [22], can be particularly
useful in determining the pathophysiology of disease,
and for devising new therapeutic strategies for diseases.
Human genetic diseases such as Sandhoff disease (a lipid
storage disorder) have been spontaneously found in dogs
[23, 24] cats [25–28] and pigs [29–31]. Among large ani-
mal models, dog and pig have been important model
species [32, 33]. However, livestock models such as
sheep may offer some advantages for developing new
large animal models of genetic disease.
Sheep as a model of human genetic disease
Sheep are feasible large animal models for genetic studies
for a number of reasons. Sheep are relatively outbred and
much more human-like than mice, due to their similar
size, and their closer genetic and physiological compos-
ition. In addition, because of this similarity sheep brains
are similar in organization to non-human primates [34].
In New Zealand, sheep are ubiquitously farmed, domes-
tic animals and therefore make cost-effective large animal
models, with highly efficient agriculture systems already
established. Their easy maintenance and acceptance of hu-
man handling saves both time and money. Sheep are also
more socially acceptable animal models for research as
compared to dogs. They are less expensive to purchase
and manage than many closely related species such as cat-
tle, particularly in New Zealand, which has a very large
sheep population of approximately 30 million sheep.
Using livestock such as sheep for medical research reflects
the complexity of outbred populations [35].
In addition to cloning, large animal models for inher-
ited diseases such as sheep can be established from nat-
urally occurring variants. Sheep and cattle animal
disease models frequently have mechanisms of disease
similar to humans at both the molecular and morpho-
logical level [36]. There are strong founder effects in the
various sheep breeds, well-established and recorded
sheep studs, and well-documented phenotypic records.
Regarding disease-causing mutations, the incidence of
homozygous affected individuals is the square of the fre-
quency of the disease allele. Therefore many deleterious
recessive mutations may accumulate to a sizeable fre-
quency, and yet homozygous affected animals may be in-
frequently seen in flocks, especially because maintenance
of production values in stud flocks requires stringent cul-
ling, and affected or diseased lambs would generally not
survive this. As a result, and because most sheep produc-
tion systems in New Zealand utilize outbred animals,
these homozygous animals may very seldom be seen on
production farms. By tracing heterozygous carriers in stud
flocks, it is relatively easy to find farms where a relatively
Pinnapureddy et al. Orphanet Journal of Rare Diseases  (2015) 10:107 Page 3 of 8
high carrier frequency exists. These can be identified and
a research flock established of carrier animals (for ex-
ample, see polycystic kidney disease sheep below).
Sheep models for many inherited disorders already
exist, such as those for inherited cataracts [37], achro-
matopsia [38], hemophilia [39, 40] and many others [8],
and some have been successfully used in testing therap-
ies for these diseases. A review in 2012, globally of
sheep, cattle and goats, of traits for which causal gene
variants were known [41] listed 14 autosomal recessive
diseases analogous to diseases such as Batten disease,
Ehlers-Danlos syndrome, inherited rickets and Gaucher
disease. Most of these mutations were Single Nucleotide
Polymorphisms (SNPs). For example, a spontaneous ani-
mal model for McArdle disease has been identified in
sheep [42] caused by a SNP. There are several well-
established sheep models of genetic disease that have
made a significant impact on our understanding of par-
ticular diseases. In the following paragraphs we present
several naturally existing sheep models of human
disease.
Sheep models of juvenile neuronal ceroid lipofuscinoses
[Batten disease, JNCL, Juvenile NCL, Spielmeyer-Vogt
disease] (ORPHA79264)
The neuronal ceroid lipofuscinoses (NCL) are a group of
recessively inherited lethal neurodegenerative diseases.
The disease in humans usually presents in previously
normal children at around 5–10 years of age, with an in-
cidence of 1 in 12500 live births [43]. Clinically, affected
individuals are characterised by brain atrophy, vision loss
due to retinopathy, seizures, and decline of mental and
motor capacities, leading to premature death in the late
teens or early adulthood. Accumulation of lysosome-
derived storage bodies in neurons and in other cells
types is a hallmark of this disease. Studies show that this
disease is caused by mutations in at least 13 different
genes, designated CLN1-CLN8, CLN10-CLN13, CLCN6
and SGSH [44]. A large number of naturally occurring
animal models that have mutations in the CLN genes
have been described (www.ucl.ac.uk/ncl)44, including
three sheep models. Mutations in CLN5 and CLN6 [9,
22, 34, 45–48] have been identified in New Zealand and
Australian sheep, and affected animals share close
clinical and pathological characteristics with the hu-
man NCLs. Research in these flocks over the last
40 years has led to many advances in the understand-
ing of Batten’s disease, such as the identification of
the “lipofuscin-like” storage material, determining the
regional nature of the cortical atrophy and its close
association with neuroinflammation, and more re-
cently the ability to trial therapeutic approaches using
drug and gene therapies [34].
Jacob sheep, a Tay-Sachs disease model [GM2 gang-
liosidosis, B, B1 variant Hexosaminidase A defi-
ciency] (ORPHA845)
GM2 gangliosidosis variant B, or Tay-Sachs disease (TSD),
is marked by accumulation of G2 gangliosides due to hex-
osaminidase A deficiency. The incidence of the disease in
non Ashkenazi Jewish populations is 1/360,000 and in the
Ashkenazi Jewish population, the incidence of TSD is 1 in
3,600. TSD is a genetically heterogeneous rare autosomal
recessive neurodegenerative disease with aggregation of
Gm2 ganglioside in the nerve cells of the central nervous
system [49]. Clinical symptoms include developmental
delay, visual inattention, and seizures, which result in a
vegetative state by 2 years of age. This disease results in
death at around 3 to 5 years of age in children, due to a
disproportionately enlarged brain caused by neuronal stor-
age of the ganglioside [49].
In 2011, a group of researchers published a report show-
ing the results of biochemical and molecular genetic ana-
lyses of four Jacob lambs diagnosed with TSD. The lambs,
which were from the same farm in Texas, were investigated
by the Texas A&M University veterinary hospital over a
three-year period [50]. Detailed physical and histological ex-
aminations of the brains have given important insights into
this genetic disease. The sheep were categorized into infant-
ile, late infantile, juvenile and adult onset forms. The infant-
ile sheep exhibited progressive clinical signs similar to the
milder condition of TSD in humans. However, histopatho-
logical findings from the brain showed a high level of simi-
larity to the human TSD patients. In contrast, attempts to
create a TSD mouse model by gene knockouts have not
been entirely successful [51,52].
A sheep model of Gaucher disease [acid beta-glucosiase
deficiency, glucocerebrosidase deficiency] (ORPHA355)
Gaucher disease (GD) is a lysosomal storage disorder
encompassing three main forms (types 1, 2 and 3), a fetal
form and a variant with cardiac involvement (Gaucher dis-
ease - ophthalmoplegia - cardiovascular calcification or
Gaucher-like disease). The overall prevalence is approxi-
mately 1/100,000. Lysosomes play a major role in living
cells with functions such as constitutive recycling and au-
tophagy [53]. Although over 300 different disease-causing
mutations have been described in humans for Gaucher
disease (GD), the lysosomal storage disorders in general
are still relatively poorly understood.
GD is an autosomal recessive disorder, and is the most
common lysosomal storage disorder with a wide range
of clinical presentations. Mutations in the gene encoding
β-glucocerebrosidase cause this disease. The three sub-
types of GD are characterized by neurologically related
problems with symptoms ranging from cytopenia, to
anemia to bone disease in the patients. Naturally occur-
ring GD has been identified in animals such as mice [54,
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55] and pigs [56]. Although a sheep model of GD had
been described previously in the 1960’s [57], a more re-
cent naturally occurring variant of GD in a Southdown
flock of sheep was identified and described in Australia
[53]. Further structural analysis showed that the gene
was highly conserved between sheep and humans and
shared a high structural similarity. Further investigations
including biochemical and histopathological examina-
tions showed that the affected neonatal lambs displayed
severe clinical signs that were highly similar to the most
severe and very rare form of this disease, GD type-2
[53]. Two mutations were identified following a muta-
tional screening and further analysis showed that one of
the two missense mutations caused the severe phenotype
of this disease [58].
A sheep model of the recessive polycystic kidney disease,
Meckel syndrome [Meckel-Gruber syndrome] (ORPHA564)
Meckel syndrome (MKS) is a rare, lethal, genetic dis-
order characterized by occipital encephalocele, large
polycystic kidneys, and polydactyly as well as associated
abnormalities that may include cleft lip/palate, cardiac
and genital anomalies, central nervous system (CNS)
malformations, liver fibrosis, and bone dysplasia. Inci-
dence has been estimated as anywhere between 1 in
3000 to 1 in 140, 000, depending on the population
studied [59].
Polycystic kidney diseases (PKD) are the most com-
mon inherited kidney disorders, in which many cysts
form in the kidneys and other organs. The exact mech-
anism of how cyst formation in the kidney is triggered
still remains to be understood [60]. In addition to the
dominant form of PKD (ADPKD), there are many less
common forms of PKD, including autosomal recessive
polycystic kidney disease (ARPKD) with an incidence of
approximately 1 in 20,000 to 1 in 40,000 live births, in-
cluding MKS, which mainly affect children and infants.
Previously, we and colleagues have described a reces-
sive form of PKD in two flocks of New Zealand sheep
[61]. These two different breeds of sheep have been fur-
ther characterized, and the recessive PKD in affected
newborn lambs were found to have phenotypic charac-
teristics similar to MKS, with a shared genetic abnormal-
ity in the 2 flocks (manuscript in preparation). Lambs
with this disorder usually die perinatally, although we
have observed that affected lambs are very occasionally
born alive (Fig. 1). MKS is invariably fatal in the peri-
natal period [62].
The sheep genome
One of the driving forces behind the success of small
animal models like mice and zebrafish is the availability
of their completely sequenced genome. Therefore, a
major advantage in the genetic characterization of
domestic farm animals is to have completely character-
ized genomes. An international consortium has recently
completed a fully annotated sequence of the sheep gen-
ome [63] which has been made available to the public
on the University of California Santa Cruz website (http://
genome.ucsc.edu/cgi-bin/hgGateway). Furthermore, the
availability of Ovine and bovine SNP chips has already im-
pacted various commercial and academic research pro-
jects in Australia and New Zealand, and large amounts of
data concerning single nucleotide variants in more than
55,000 sheep have already been generated. Using this SNP
information together with current genomic technologies
and methods, in silico identification of disease–causing
mutations and embryonic lethal variants is possible. This,
together with the vast amounts of phenotypic data that
have already been collected by the NZ sheep industry, al-
lows the possibility of systematic screening for the identifi-
cation of putative disease-causing variants. Furthermore,
the sheep industry in New Zealand has pedigree informa-
tion on millions of animals, including those that have
genotype information. Therefore there is infrastructure in
the industry that can allow animals or flocks of animals
harboring specific gene variants of interest to be easily
identified and sourced in the population.
NGS and the identification of new sheep models of
disease
Since its invention in the 1970’s by Frederick Sanger,
DNA sequencing has promulgated a major revolution in
genetic research. The human genome project, which
began in 1990, took 13 years and cost $2.7 billion to
completely sequence the first human genome. The infor-
mation gained through the completion of this project
has played an important role in studying various mono-
genic and complex polygenic diseases. With the advent
Fig. 1 Photograph of an affected newborn lamb with a recessive
polycystic kidney disease
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of NGS technology, it now takes approximately 3 days
to completely sequence a human genome and costs
only a few thousand dollars. This has provided the
ability to carry out experiments that were previously
unfeasible, and indeed NGS techniques have revolu-
tionised the way scientists approach solving complex
genetic problems in many fields of genomic research
including microbiology, oncology, genetics and vir-
ology [64]. Moreover, equivalent efforts have also
been carried out by the NIH (USA) and the U.S.
Department of Agriculture, which has resulted in a
completely characterized bovine genome sequence
[65](http://bovinegenome.org/), and this therefore
provides the opportunity for comparative genomic
analysis between ovine, bovine and human.
The cost and time for NGS DNA sequencing has
been lowered by orders of magnitude, and so it is
now feasible to screen populations of sheep for
genetic variants that resemble human genetic dis-
eases. Indeed, this work is already well underway as
part of production value surveys for variables associ-
ated with commercially important attributes, such as
parasite resistance, growth rates and wool pro-
duction, and with help from NZORD and collaborat-
ing organisations early-stage experiments have been
started.
Conclusions and future directions
The use of a diverse range of animal models, cover-
ing all aspects of disease manifestations at both the
genotypic and phenotypic level allows for greater in-
sights into disease mechanisms. The identification of
natural variants of genetic disease in sheep is a first
step towards the possibility of successfully establish-
ing new sheep models for human genetic diseases.
Indeed, ovine models of genetic disease such as the
GD model have shown their worth as excellent pre-
clinical models. Clearly, NGS will continue to play a
role in the characterization of spontaneous genetic
diseases arising in sheep, and will help to generate
new ovine models of human genetic disease. How-
ever, it is now feasible to screen populations of
sheep for genetic variants that resemble human gen-
etic diseases, and with an appropriate investment in
sequencing and bioinformatics resources, one pos-
sible future direction could be to use this NGS ap-
proach as a way to search for, and via carrier-carrier
crosses, generate new ovine models of human gen-
etic disease. The adoption of this approach could po-
tentially result in a many-fold expansion of the
numbers of ovine models of human disease, which
would then help to realize both human and animal
therapeutic benefits.
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